Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average - What's Next?

Key Points

• Iovance shares fell 35.4% to $9.56 and crossed below their 50-day moving average of $11.38 on exceptionally heavy trading volume, reflecting significant investor repositioning.
• Updated IOV-LUN-202 data showed a 24.6% response rate in previously treated non-squamous metastatic lung cancer, rising to 43.3% in KRAS wild-type patients and 59.1% in a biomarker-enriched subgroup. Iovance plans a supplemental application for lifileucel in 2027, with the POSITILITY registrational study expected to begin enrollment in November 2026.
• Although analysts remain broadly positive—with a “Moderate Buy” consensus and an average $13.20 price target—investors questioned whether the overall efficacy is broad enough for lung-cancer expansion, while upcoming earnings and an expected full-year loss add risk.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $11.38 and traded as low as $9.35. Iovance Biotherapeutics shares last traded at $9.56, with a volume of 58,772,732 shares.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with previously treated non-squamous mNSCLC, consistent with previously reported results. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched subgroup reached 59.1%, supporting further precision-medicine development. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: The company said IOV-LUN-202 enrollment is nearing completion and plans to use the results to support a supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. A biomarker-enriched registrational study, POSITILITY, is expected to begin enrollment in November 2026. Iovance Lung Cancer Strategy
• Positive Sentiment: Recent melanoma and other solid-tumor data, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, reinforced optimism about the broader lifileucel platform. Analysts at Zacks also upgraded IOVA to “strong buy.” Lifileucel Shows 50% Response Rate
• Neutral Sentiment: Options activity was elevated, with traders purchasing 28,173 call options—about 70% above typical daily call volume—indicating increased speculative interest ahead of the data and upcoming earnings report.
• Negative Sentiment: Despite the headline-positive results, investors focused on the overall 24.6% response rate and the sharp difference between biomarker-defined subgroups. The market reaction suggests concerns that the data may not demonstrate broad enough efficacy for lung-cancer expansion, or may require a narrower targeted population than previously expected. Iovance Stock Reaction to Lung Cancer Data
• Negative Sentiment: The sharp decline occurred on volume far above average, suggesting substantial investor repositioning rather than a minor market fluctuation. Upcoming earnings expectations for a quarterly loss remain an additional source of risk.

Analyst Ratings Changes

Several research firms recently issued reports on IOVA. Barclays boosted their target price on shares of Iovance Biotherapeutics from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Tuesday, October 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a report on Tuesday, September 29th. Citizens Jmp increased their price target on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. The Goldman Sachs Group initiated coverage on Iovance Biotherapeutics in a research report on Thursday, September 24th. They issued a "buy" rating and a $15.00 price objective for the company. Finally, Robert W. Baird lifted their price objective on Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a "neutral" rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $13.20.

Iovance Biotherapeutics Trading Down 35.4%

The company has a market cap of $4.33 billion, a price-to-earnings ratio of -13.10 and a beta of 0.76. The stock's 50-day moving average is $11.38 and its 200-day moving average is $5.79.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million during the quarter, compared to analysts' expectations of $87.83 million. During the same period last year, the company posted ($0.33) earnings per share. The business's quarterly revenue was up 65.7% on a year-over-year basis. As a group, analysts predict that Iovance Biotherapeutics, Inc. will post -0.45 EPS for the current year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Iovance Biotherapeutics in the second quarter valued at $153,744,000. Palo Alto Investors LP acquired a new position in shares of Iovance Biotherapeutics during the second quarter valued at about $22,032,229. Bank of America Corp DE bought a new stake in shares of Iovance Biotherapeutics during the second quarter worth about $20,773,000. Mirador Capital Partners LP increased its position in shares of Iovance Biotherapeutics by 1.4% during the third quarter. Mirador Capital Partners LP now owns 1,095,740 shares of the biotechnology company's stock worth $16,239,000 after acquiring an additional 15,452 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Iovance Biotherapeutics by 71.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company's stock worth $9,282,000 after acquiring an additional 1,106,592 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.